Drug Profile
Research programme: autologous T-cell therapy - Iovance Biotherapeutics
Alternative Names: HPV TILLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA); National Institutes of Health (USA)
- Developer H. Lee Moffitt Cancer Center and Research Institute; Iovance Biotherapeutics; National Cancer Institute (USA); Roswell Park Cancer Institute
- Class Antineoplastics; Cell therapies; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bladder cancer; Breast cancer; Human papillomavirus infections; Lung cancer; Non-small cell lung cancer
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (Parenteral)
- 16 May 2019 Genocea Biosciences and Iovance Biotherapeutics enters into a collaboration to assess Genocea’s technology platform for tumour-infiltrating lymphocyte product development
- 28 Feb 2019 No recent reports of development identified for preclinical development in Bladder-cancer in USA (Parenteral)